Quick Answer
Pyxis Oncology, Inc. reported R&D Expense of $73.70 million for fiscal year 2025.
Pyxis Oncology, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $73.70M | +25.4% |
| 2024 | $58.75M | +18.5% |
| 2023 | $49.59M | -42.4% |
| 2022 | $86.13M | +68.7% |
| 2021 | $51.05M | +464.3% |
| 2020 | $9.05M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.81M | +0.4% | +3.9% |
| June 30, 2025 | $17.13M | +22.8% | +0.5% |
| March 31, 2025 | $17.04M | +30.8% | -3.9% |
| September 30, 2024 | $17.74M | +20.8% | +27.1% |
| June 30, 2024 | $13.95M | +22.5% | +7.1% |
| March 31, 2024 | $13.03M | +9.5% | -11.3% |
| September 30, 2023 | $14.69M | -22.8% | +28.9% |
| June 30, 2023 | $11.39M | -33.7% | -4.3% |
- Pyxis Oncology, Inc. showed an increase of +25.4% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Pyxis Oncology, Inc.’s r&d expense has grown by 714.5% (from $9.05 million to $73.70 million).
- The most recent figure is from Pyxis Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: